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Abstract: 
Background: The SITS-UTMOST (Upper Time window Monitoring Study) was a registry-
based prospective study of intravenous alteplase used in the extended time window (3-4.5h) 
in acute ischaemic stroke to evaluate the impact of the approval of the extended time window 
on routine clinical practice. 
Methods: Inclusion of at least 1,000 patients treated within 3-4.5 hours according to the 
licensed criteria and actively registered in the SITS-International Stroke Thrombolysis 
Registry was planned. Prospective data collection started 2 May 2012 and ended 2 November 
2014. A historical cohort was identified for 2 years preceding May 2012. Clinical 
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management and outcome were contrasted between patients treated within 3h versus 3-4.5h 
in the prospective cohort and between historical and prospective cohorts for the 3h time 
window. Outcomes were functional independency (modified Rankin Scale, mRS) 0-2, 
favourable outcome (mRS 0-1), and death at 3-months and symptomatic intracerebral 
haemorrhage (SICH) per SITS.  
Results: 4157 patients from 81 centres in 12 EU countries were entered prospectively 
(N=1118 in the 3-4.5h, N=3039 in the 0-3h time window) and 3454 retrospective patients in 
the 0-3h time window who met the marketing approval conditions. In the prospective cohort, 
median arrival to treatment time was longer in the 3-4.5h than 3h window (79 vs. 55 
minutes). Within the 3h time window, treatment delays were shorter for prospective than 
historical patients (55 vs. 63). There was no significant difference between the 3-4.5h versus 
3h prospective cohort with regard to percentage of reported SICH (1.6 vs. 1.7), death (11.6 
vs. 11.1), functional independency (66 vs. 65) at 3months or favourable outcome (51 vs. 50). 
Conclusion: This study identified no negative impact on treatment delay, nor on outcome, 
following extension of the approved time window to 4.5 h for use of alteplase in stroke. 
 
BACKGROUND 
Intravenous (iv) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is a 
highly effective treatment within 3 hours after onset of stroke symptoms in selected patients 
with acute ischaemic stroke.1-6 An extended treatment window up to 4.5 hours has also 
proven to be efficacious in the randomised ECASS III trial7 and recent meta-analysis6 which 
is supported by observational SITS- International Stroke Thrombolysis Registry studies.8,9,10 
Safety and efficacy of a treatment in acute ischaemic stroke may differ between the settings 
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of RCTs and during implementation into clinical routine. Recent studies have shed some light 
into the importance of optimising hospital management of stroke patients in the acute 
phase.11-14 Guidelines recommend to treat with iv thrombolysis in acute ischemic stroke if 
symptoms onset is within 4.5 hours.15,16 
 
The SITS- UTMOST (Upper Time window Monitoring Study) was a registry-based 
prospective observational study carried out upon post-approval request of the Competent 
Authorities in European Union (EU) with Mutual Recognition Procedure (MRP)-countries of 
intravenous (iv) thrombolysis by Actilyse in the extended time window (3-4.5h) after onset of 
acute ischaemic stroke symptoms. Authorities were concerned that extending the time 
window might lead to patients being treated more slowly with increased door to needle 
(DNT) times. The purpose of this study was to evaluate the impact of the approval of the 
extended time window up to 4.5 hours on routine clinical practice treated according to the EU 
Summary of Product Characteristics (SmPC) criteria.  
 
Methods: 
At least 1,000 patients treated by iv thrombolysis within 3-4.5 hours time window after onset 
of acute ischaemic stroke from EU centres actively registered in the SITS-International 
Stroke Thrombolysis Registry (ISTR) were planned to be included in the study. The sample 
size of the study was not based on any formal power calculation, rather chosen pragmatically 
in consultation with authorities, based on numbers achievable within a 2 year period. 
Controls were also recorded: 0-3h prospective and historical.  
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Centre selection 
Ninety-four centres from EU countries were considered to be included in the post-approval 
part of the study based on their active participation in SITS-ISTR during 2010 and 2011. The 
criteria used to select centres required regular treatment of acute ischaemic stroke patients 
with Actilyse and registered into SITS registry (> 1 patient/ month during January 2010 and 
January 2012) with sufficient quality of the data; completeness of three months outcome data 
> 70% and acute data >75%.  
 
The prospective part of the registry commenced on 2 May 2012 after the majority of EU 
Health Authorities had approved the extended AIS treatment time window up to 4.5 hours 
(except for Poland and Italy where the start date based on local approvals had been set to 15 
July 2010 and 3 October 2013, respectively). UTMOST database was locked on 2 November 
2014 when reached target for at least 1000 patients in the 3-4.5h time window. A historical 
cohort for the prior 2 years was extracted from the registry from the same centres that 
contributed to the prospective cohort, dated 1 May 2010 to 1 May 2012 except for Poland and 
Italy. For Poland, retrospective cohort data extraction was from 15 July 2008 to 14 July 2010 
and for Italy was 3 October 2011 to 2 October 2013. 
 
All centres routinely providing data to the academic SITS-ISTR Registry were informed 
about the study through the SITS website (website: sitsinternational.org/sits-projects/sits-
utmost), regardless of their actual participation. SITS-UTMOST extracted data from the 
existing academic registry SITS-ISTR. Centres, chosen for the purposes of SITS-UTMOST 
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data analysis, were contacted prior to final data analysis to confirm agreement for having 
their data included in the study. All centres agreed to include their data in the analysis.  
 
The SITS-ISTR is an ongoing, prospective, internet-based, academic-driven, multinational, 
observational monitoring register for clinical centers using thrombolysis for the treatment of 
acute ischemic stroke. The methodology of the SITS-ISTR, including procedures for data 
collection and management, patient identification and verification of source data, has been 
described previously.2,8,9 We collected baseline and demographic characteristics, stroke 
severity as measured by NIHSS score, time logistics, medication history, and imaging data on 
admission and 24 hours after thrombolysis (preferably within 22-36 hours or earlier if 
clinically indicated) and follow-up, 3-months outcome as measured by modified Rankin 
Scale (mRS) score. 
 
Ethics approval and data monitoring 
The study was approved by Ethics Committee Karolinska Institutet, Stockholm. Ethics 
approval and patient consent for participation in the SITS-ISTR were obtained in countries 
that required this; other countries approved the register for anonymized audit. The SITS 
International Coordination Office monitored the SITS-ISTR data online and checked 
individual patient data monthly to identify errors or inconsistencies. The study was performed 
according to a protocol approved by the ethics committee. Since the study is not an RCT and 
did not influence treatment allocation it did not require clinical trial registration.   
 
Outcome measurements  
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Primary outcome measurements were symptomatic intracerebral haemorrhage (SICH), 
death and independency as measured by the modified Rankin Scale (mRS) and favourable 
outcome (mRS 0-1) at 3-months  
Secondary outcome measurements were patients’ management time delays: Onset of 
symptoms to treatment/needle time and its components: onset of symptoms to door; door to 
imaging scan, imaging to needle and door to needle times (DNT).  
 
The following definitions of SICH were used in our study:  
(1) SICH per SITS-MOST: PH2 (parenchymal haemorrhage type 2) or remote 
parenchymal haemorrhage type (PHr2) on imaging 22–36 hours after treatment, or 
earlier if the scan was performed due to clinical deterioration, combined with a 
neurological deterioration of ≥4 NIHSS points or leading to death within 24 hours;  
(2) SICH per ECASS II: any ICH on any post-treatment imaging after the start of 
thrombolysis and increase of ≥4 NIHSS points or leading to death, within 7 days;  
(3) SICH per NINDS: any ICH on any post-treatment imaging and any deterioration in 
NIHSS or death within 7 days.  
All SICH events were adjudicated centrally by the SITS International Coordination Office 
based on submitted clinical and imaging reports; images were not available for review. All 
assessments of imaging studies, neurological and functional status were done according to 
clinical routine at centers participating in the SITS-ISTR. Training in mRS assessment was 
not mandated by SITS. 
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Statistical analysis 
We contrasted baseline data and clinical outcome data by comparing between patients treated 
within 3h and 3-4.5h in the post-approval/prospective cohort. We also compared the pre-
approval/ retrospective cohort to post-approval/prospective cohort for patients treated within 
3 hours. For categorical variables, we calculated percentage proportions by dividing the 
number of events by the total number of patients excluding missing or unknown cases. 
Pearson’s Chi square tests were used for categorical variables and Mann–Whitney U tests 
were used for continuous and ordinal variables. We further compared the proportions of 
functional independency and death and SICH. Analyses were also made with regards to 
patient’s management time intervals to evaluate if an extended time window results in undue 
delays in treatment. We also performed multivariable logistic regression analysis after 
adjusting for variables that were statistically significant in the univariate analysis at 10% 
level. All p-values presented are at nominal 5% alpha level as statistically significant. 
 
RESULTS  
Twelve European countries recorded data in the registry during the prospective study period; 
Belgium, Bulgaria, Czech Republic, Finland, Germany, Italy, Poland, Portugal, Slovenia, 
Spain, Sweden, United Kingdom 
 
RECRUITMENT OF PATIENTS  
In the prospective cohort, 4157 patients and in the retrospective cohort, 3454 patients were 
recorded to have received iv thrombolysis according to the EU SmPC. Among the 
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prospective cohort, 1118 patients were treated with iv thrombolysis between 3 and 4.5h from 
onset of stroke. 
 
Recruitment per country is shown in appendix 1.  
BASELINE AND CLINICAL DATA 
Baseline and clinical characteristics of patients in full compliance with other European SmPC 
for the prospective and retrospective cohorts are given in Table 1. The proportion of females 
was higher in the upper time window (3-4.5h) compared to ≤3h time window (45% vs. 41%). 
Frequency of hyperlipidemia and atrial fibrillation was lower in the upper time window 
compared to ≤3h time window. Baseline stroke severity was 2 points (median) lower in the 3-
4.5h time window period compared to ≤3h time window and median NIHSS score was 1 
point lower in the prospective 3h cohort than retrospective 3h. In general the patient baseline 
characteristics treated within 3 hours were very similar in the prospective and retrospective 
cohorts. 
 
TIME LOGISTICS OF PATIENTS’ MANAGEMENT 
Table 2 shows the time logistics. The management times within the hospital are somewhat 
longer for the 3-4.5h time window compared to the < 3h time window. Median door to 
imaging time was 7 minutes and DNT was 24 minutes longer in the 3-4.5h time window 
compared to the < 3h time window. Median DNT was 8 minutes shorter in the <3h 
prospective cohort compared to <3h retrospective cohort. 
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In Table 3, the hospital management time is presented based on when the patient arrived to 
the hospital (i.e. prehospital time). For the prospective cohort (<4.5h treatment time window), 
in hospital management times (door to imaging and DNT) were shorter for patients whose 
stroke onset to hospital arrival time was longer. When comparing patients who arrived 
hospital within 60 minutes of symptom onset between prospective and historical control, we 
observed a 9 minutes shorter median DNT in the prospective compared to historical control 
and similar DNT (median 60 minutes) for patients who arrived hospital within 61-120 
minutes of symptom onset. 
 
CLINICAL OUTCOME DATA 
Table 4 shows proportion and adjusted odds ratio for the SICH and 3 months outcomes. In 
the prospective cohort, there was no significant difference in proportions of SICH mortality 
and functional outcome at 3 months between 3-4.5h and <3h time window. Multivariate 
analyses showed no difference in SICH and mortality between 3-4.5h and <3h time window 
in the prospective cohorts. There was a significantly lower odds ratio for functional 
independence at 3-months in the 3-4.5h cohort compared to <3h cohort.  
In the <3h time window, there was no significant difference in any outcome parameter 
between the prospective and retrospective cohort.  
 
Figure 1 shows the similar distribution of mRS score at 3 months between the cohorts. 
 
DISCUSSION  
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During the 30 months of the prospective study period, the SITS-UTMOST registry achieved 
the expected sample size of more than 1000 patients treated within the extended time window 
(3-4.5h) fulfilling all other SmPC criteria. In the prospective cohort, there were minor 
differences in the baseline and demographic characteristics between 3-4.5h and ≤3h time 
window which are not clinically important. The only clinically important difference was 2 
points lower baseline median NIHSS score in the 3-4.5h time window than the ≤3h in 
prospective cohort which favoured 3-4.5h time window. This may either represent milder 
stroke patients seeking hospital later than severe stroke or a greater proportion of patients 
with milder stroke severity being treated in recent years compared to previous years. When 
comparing ≤3h time window between prospective and retrospective cohorts, in general the 
baseline and demographic characteristics were very similar. Most of the statistically 
significant differences were not clinically significant other than 1 point lower median NIHSS 
score in the ≤3h prospective cohort than in the ≤3h retrospective cohort.  
 
As we observed in previous studies8,-10, there was a longer hospital management time (7 
minutes longer median door to imaging time and 24 minutes longer median DNT) in the 3-
4.5h time window compared to ≤3h time window. Patients treated in the 3-4.5h time window 
had milder strokes which may have led to different management at the hospital. It is 
important to note that the median DNT in the prospective ≤3h time window was 8 minutes 
shorter than in the corresponding ≤3h retrospective cohort. Some patients in the 3-4.5h cohort 
might not have received treatment under the original licence due to ≤3h time window 
restriction. After extension of the time window beyond 3h, centres would have more time to 
assess and thus greater potential to treat such patients with IV thrombolysis. 
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We also observed that in hospital management times (door to imaging, DNT) were longer 
when stroke onset to hospital arrival time was shorter (stroke Onset to Door time). These 
results may suggest that patients arriving at the limit of therapeutic time window are managed 
more rapidly than those arriving earlier. However, this interpretation may not be the sole 
explanation. It may be due to a mathematical reason since we have an upper time limit for 
start of treatment (4.5h for prospective and 3h for historical control). It is important to note 
that there was no negative impact on hospital management time for patients who arrived 
hospital within first 2 hours of symptom onset between the prospective and historical control. 
However, 60 minutes DNT is still long and hospitals should aim for DNT less than 40 
minutes.   
 
In the prospective cohort, we did not observe any difference in the SICH, mortality and 
functional outcome between the 3-4.5h and ≤3h time window. A similar observation was also 
noted for ≤3h prospective and retrospective cohorts. These results were consistent in the 
multivariable analysis after adjustment for baseline imbalances, with the exception of a lower 
odds ratio for functional independence (mRS 0-2) at 3-months in the 3-4.5h cohort compared 
to ≤3h cohort. It is biologically plausible that later initiation of treatment will mean that the 
amount of core damage which is already established will be greater, and the salvageable 
penumbral tissue smaller, readily explaining this finding. 
 
In conclusion, this observational study uncovered no evidence of poorer safety or functional 
outcome from treatment with iv thrombolysis in the 3-4.5h time window after acute 
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ischaemic stroke. Importantly, the absolute number of patients treated within a 3h time 
window in the prospective cohort remained steady since extension of the licensed time 
window. We did not observe a negative impact of the extended time window on the hospital 
management logisitics compared to those of the historically treated ≤3h time window 
patients. The extended hospital management time for patients in the 3-4.5h cohort is 
suboptimal and indicates scope for service improvement. This should have high priority since 
repeated pooled analyses have consistently shown that earlier initiation of treatment increases 
the odds for better outcome3,4,6.  
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Figure legends 
Figure 1 Modified Rankin scale score at 3m 
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Table 1. Baseline and clinical characteristics  
Baseline and 
demographic 
variables 
Prospective     
3–4∙5 h 
(n=1118) 
Prospective 
within 3 h 
(n=3039) 
*p-
values 
Retrospective 
within 3 h 
(n=3454) 
**p-
values 
Age (years)  68 (58-75) 68 (59-75) 0.553 68 (59-75) 0.948 
Sex: female 498/ 1118 (44.5) 1239/ 3039 (40.8) 0.031 1428/ 3454 (41.3) 0.658 
Hypertension 699/ 1114 (62.8) 1876/ 3034 (61.8) 0.616 2134/ 3433 (62.2) 0.806 
Diabetes mellitus  217/ 1117 (19.4) 494/ 3033 (16.3) 0.020 559/ 3439 (16.3) 0.999 
Hyperlipidaemia 307/ 3433 (27.5) 941/ 3021 (31.2) 0.027 1088/ 3382 (32.2) 0.395 
Smoking 
current  
previous 
 
204/ 1090 (18.7) 
128/ 1090 (11.7) 
 
566/ 2922 (19.4) 
347/ 2922 (11.9) 
0.878  
662/ 3306 (20.0) 
461/ 3306 (13.9) 
0.028 
Previous stroke >3 
months before 
105/1116 (9.4) 276/ 3027 (9.1) 0.821 
286/ 3435 (8.3) 
0.279 
Previous TIA 79/ 1117 (7.1) 183/ 3028 (6.0) 0.256 218/ 3037 (7.2) 0.084 
Atrial fibrillation 146/ 1116 (13.1) 481/ 3028 (15.9) 0.029 655/ 3433 (19.1) 0.001 
Congestive heart 
failure 
75/ 1114 (6.7) 192/ 3023 (6.4) 0.710 
233/ 3439 (6.8) 
0.525 
Aspirin 310/ 1110 (27.9) 874/ 3017 (29.0) 0.537 1067 / 3435 (31.1) 0.072 
Dipyridamol 14/ 1114 (1.3) 45/ 3022 (1.5) 0.681 82/ 3442 (2.4) 0.013 
Clopidogrel 86/ 1113 (7.7) 168/ 3022 (5.6) 0.012 167/ 3443 (4.9) 0.220 
Other Anti-platelet 8/ 1114 (0.72) 25/ 3021 (0.83) 0.878 50/ 3442 (1.5) 0.026 
Oral anti-
hypertensives 
628/ 1111 (56.5) 1742/ 3019 (57.7) 0.521 
1882/ 3429 (54.9) 
0.025 
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Statin 326/ 1113 (29.3) 947/ 3019 (31.4) 0.213 852/ 3021 (28.2) 0.008 
Current infarct at 
baseline imaging 
167/ 1099 (15.2) 425/ 2991 (14.2) 0.457 
502/ 3363 (14.9) 
0.439 
Weight in kg 78 (70-90) 79 (70-90) 0.430 78 (69-89) 0.013 
Dose of Actilyse 
(mg) 
70 (61-80) 70 (61-80) 0.546 
70 (60-80) 
 
Blood glucose 
(mmol/L) 
6.7 (5.7-8.0) 6.5 (5.7-7.8) 0.281 
6.5 (5.7-7.8) 
0.810 
NIHSS) score 8 (5-14) 10 (6-16) <0.001 11 (6-17) 0.002 
Systolic blood 
pressure (mm Hg) 
150 (135-162) 150 (135-163) 0.301 
150 (135-160) 
0.159 
Diastolic blood 
pressure (mm Hg) 
80 (72-90) 80 (73-90) 0.219 
80 (72-90) 
0.332 
*Comparison between 3-4.5h and ≤3h for the prospective cohort and ** comparison between ≤3h 
prospective and ≤3h retrospective cohorts. Data are median (IQR) for continuous and ordinal 
variables and n/N (%) for categorical variables 
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Table 2. Time logistics according to onset to treatment time 
Median (IQR) Time 
logistics in minutes  
Prospective 
3–4∙5h 
(n=1118) 
Prospective 
within 3h 
(n=3039) 
 
p-
values* 
Retrospective 
within 3h 
(n=3454) 
 
p-
values** 
Stroke onset to door 
time 
137 (100-171) 67 (50-90) 
<0.001 
65 (46-86) 
<0.001 
Door to imaging 29 (17-47) 22 (13-32) <0.001 23 (14-35) 0.002 
Imaging to treatment 45 (28-70) 32 (20-48) <0.001 37 (24-55) <0.001 
Door to needle time 79 (54-111) 55 (40-75) <0.001 63 (45-84) <0.001 
Stroke onset to 
treatment time 
217 (200-240) 129 (105-155) 
<0.001 
135 (106-157) 
<0.001 
*Comparison between 3-4.5h and ≤3h for the prospective cohort and **between ≤3h prospective and 
≤3h retrospective cohorts using Mann-Whitney U Test.  
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Table 3. Time logistics of patients within the prospective cohort depending on arrival time to 
hospital (OTD onset to door). Data for retrospective cohort is provided for the first 2 hours of hospital 
arrival 
 Prospective cohort  Retrospective cohort 
Time in 
minutes 
OTD 
181-270 
(n=211) 
OTD 
121-180 
(n=604) 
OTD 
61-120 
(n=1865) 
OTD             
0-60 min 
(n=1321) 
p-
values
* 
OTD 
61-120 
(n=1592) 
OTD             
0-60 min 
(n=1535) 
Door to 
imaging  
18 (11-28) 21 (13-
32) 
23 (14-35) 24 (15-35) 0.001 21 (12-
32) 
26 (15-39) 
Imaging to 
needle time 
25 (15-33) 34 (20-
48) 
37 (22-55) 35 (23-57) <0.00
1 
35 (23-
50) 
40 (26-60) 
Door to 
needle time 
43 (30-55) 58 (40-
76) 
60 (45-85) 61 (45-90) <0.00
1 
60 (43-
75) 
70 (52-93) 
Onset to 
treatment  
250 (240-
260) 
205 (185-
226) 
150 (126-
175) 
110 (90-
135) 
<0.00
1 
145 (129-
165) 
115 (95-
135) 
*Comparison using Kruskal-Wallis equality-of-populations rank test for all groups for the prospective 
cohort. Data are median (IQR). 156 patients excluded from this analysis due to unclear OTD time   
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Table 4. SICH and 3-months outcomes  
Outcomes Prospective 
3–4∙5h 
n/N (%) 
aOR (95% CI) 
Prospective 
within 3h 
n/N (%) 
aOR (95% CI) 
p-
values* 
Retrospective 
within 3h 
n/N (%) 
aOR (95% CI) 
p-
values** 
SICH (SITS-MOST)1 
Adjusted OR 
17/ 1082 (1.57) 
1.08 (0.61-1.90) 
49/ 2953 (1.66) 
-- 
0.956 
0.787 
60/ 3391 (1.77) 
0.91 (0.61-1.35) 
0.811 
0.639  
SICH (ECASS II)2 
Adjusted OR 
42/ 1074 (3.91) 
1.46 (0.99-2.15) 
97/ 2946 (3.29) 
-- 
0.395 
0.053 
131/ 3369 (3.89) 
0.87 (0.65-1.15) 
0.231 
0.331 
SICH (NINDS)3 
Adjusted OR 
59/ 1081 (5.46) 
1.35 (0.98-1.87) 
144/ 2950 (4.88) 
-- 
0.509 
0.068 
194/ 3386 (5.7) 
0.89 (0.70-1.12) 
0.149 
0.326 
3 months (mRS 0–1) 
Adjusted OR 
399/ 782 (51.0) 
0.87 (0.72-1.05) 
1109/ 2230 (49.7) 
-- 
0.562 
0.159 
1450/ 2951 (49.1) 
0.96 (0.84-1.09) 
0.692 
0.514 
3 months (mRS 0–2) 
Adjusted OR 
512/ 782 (65.5) 
0.81 (0.67-0.99) 
1453/ 2230 (65.2) 
-- 
0.908 
0.044 
1878/ 2951 (63.4) 
1.01 (0.88-1.15) 
0.272 
 0.925 
3 months mortality  
Adjusted OR 
93/ 801 (11.6) 
1.30 (0.98-1.73) 
251/ 2267 (11.1) 
-- 
0.726 
0.066 
333/ 3021 (11.0) 
1.10 (0.90-1.34) 
0.990 
0.339 
SICH=symptomatic intracerebral haemorrhage; mRS=modified Rankin scale, aOR= Adjusted Odds 
Ratio. *For the prospective 3-4.5h compared to prospective ≤3h cohort. Multivariate analysis adjusted 
for age, sex, baseline NIHSS, history of diabetes mellitus, hyperlipidaemia and atrial fibrillation and 
treatment with Clopidogel at baseline. ** For ≤3h prospective cohort compared to ≤3h retrospective 
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cohort. Multivariate analysis adjusted for age, baseline NIHSS, history of TIA, atrial fibrillation, and 
smoking, aspirin, antihypertensive and statin treatment at baseline. 
 
1 A local or remote parenchymal haemorrhage type 2 on the 22- to 36-h post-treatment imaging scan 
or earlier if clinically indicated, combined with a neurological worsening of ≥4 points between 
baseline and 24 h, or leading to death 
2 Any intracerebral haemorrhage on any post-treatment imaging scans combined with NIHSSS 
worsening ≥4 points between baseline and 7d, or leading to death 
3 Any intracerebral haemorrhage on any post-treatment imaging scans combined with any decline in 
neurologic status as measured by NIHSS between baseline and 7d, or leading to death 
 
 
Figure 1 
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Appendix 1 Recruitment of patients per country (supplementary table) 
 Prospective cohort Retrospective cohort 
Country Number Percentage Number Percentage 
Belgium 59 1.4 39 1.1 
Bulgaria 87 2.1 35 1.0 
Czech Republic 854 20.5 456 13.2 
Finland 38 0.9 148 4.3 
Germany 242 5.8 318 9.2 
Italy 595 14.3 798 23.1 
Poland 266 6.4 131 3.8 
Portugal 192 4.6 201 5.8 
Slovenia 72 1.7 44 1.3 
Spain 127 3.1 54 1.6 
Sweden 361 8.7 247 7.2 
UK 1264 30.4 983 28.5 
Total 4157 100 3454 100 
 
 
 
